10-year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy
Top Cited Papers
- 1 September 2001
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 51 (1), 31-40
- https://doi.org/10.1016/s0360-3016(01)01601-7
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Modern prostate brachytherapyCancer, 2000
- PROSTATE SPECIFIC ANTIGEN BOUNCE AFTER RADIOACTIVE SEED IMPLANTATION FOLLOWED BY EXTERNAL BEAM RADIATION FOR PROSTATE CANCERJournal of Urology, 2000
- Clinical Utility of the Percentage of Positive Prostate Biopsies in Defining Biochemical Outcome After Radical Prostatectomy for Patients With Clinically Localized Prostate CancerJournal of Clinical Oncology, 2000
- Palladium-103 brachytherapy for prostate carcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2000
- Post-treatment PSA ≤0.2 ng/ml defines disease freedom after radiotherapy for prostate cancer using modern techniquesUrology, 1999
- Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic CancerJournal of Clinical Oncology, 1999
- The Pathologist as OptimistThe American Journal of Surgical Pathology, 1998
- Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Correlation of Prostate Needle Biopsy and Radical Prostatectomy Gleason Grade in Academic and Community SettingsThe American Journal of Surgical Pathology, 1997